CIK 0001759138 · Non-accelerated filer<br>Smaller reporting company
Cabaletta Bio, Inc.
Sign in to watch- Ticker
- CABA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 759-3100
- Business address
- 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-19 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +38,238 | 38,238 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −113,500 | 0 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +113,500 | 113,500 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −135,000 | 0 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −150,000 | 0 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −130,000 | 0 | ||
| 2025-05-19 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2025-03-03 | Binder Gwendolyn President, Science & Tech. | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2025-03-03 | Marda Anup Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2025-03-03 | Gerard Michael General Counsel | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-03-03 | Das Arun Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-03-03 | Chang David J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2025-03-03 | Nichtberger Steven President & CEO | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2024-06-03 | Bollard Catherine Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2024-06-03 | Simon Mark Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2024-06-03 | HENRIQUES RICHARD C JR Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2024-06-03 | Brun Scott C. Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2024-06-03 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 |
Page 7 of 13 · 256 trades